H.C. Wainwright raised the firm’s price target on Mineralys Therapeutics (MLYS) to $52 from $42 and keeps a Buy rating on the shares. The firm says its key onion leader conversations on the unmet need for resistant and uncontrolled hypertension patients is “supportive” of lorundrostat’s profile in uncontrolled and resistant hypertension.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLYS:
- Mineralys Therapeutics completes enrollment in Phase 2 EXPLORE-OSA trial
- Insiders Pour Millions into These 2 Stocks — Goldman Sachs Backs the Move
- Mineralys Therapeutics falls -4.9%
- Mineralys Therapeutics price target raised to $50 from $26 at Wells Fargo
- Buy Rating for Mineralys Therapeutics, Inc. Driven by Promising Phase 3 Results and Strong Financial Position